This trial is active, not recruiting.

Condition coronary artery disease
Treatment resolute onyx stent - 2.25 mm - 4.0 mm
Sponsor Medtronic Vascular
Start date April 2015
End date July 2016
Trial size 75 participants
Trial identifier NCT02419521, Version 2.0 - 23Mar2015


The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Intervention model single group assignment
Primary purpose treatment
Masking no masking
Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Core (2.25 mm - 4.0 mm)
resolute onyx stent - 2.25 mm - 4.0 mm

Primary Outcomes

In-stent Late Lumen Loss as measured by quantitative coronary angiography
time frame: 8 Months

Secondary Outcomes

Cardiac Death
time frame: 8 Months
Target Vessel Myocardial Infarction (TVMI)
time frame: 8 Months
Target Lesion Revascularization (TLR)
time frame: 8 Months
Major Adverse Cardiac Event (MACE)
time frame: 8 Months
Target Lesion Failure (TLF)
time frame: 8 Months
Target Vessel Failure (TVF)
time frame: 8 Months
Stent Thrombosis (ST)
time frame: 8 Months

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - Must be an acceptable candidate for percutaneous coronary intervention (PCI), stenting, and emergent coronary artery bypass graft (CABG) surgery - Must have clinical evidence of ischemic heart disease, stable or unstable angina, and/or a positive functional study - Must require treatment of either a) a single target lesion amenable to treatment OR b) two target lesions located in separate target vessels - Target lesion(s) must be de novo lesion(s) in native coronary artery(ies) Exclusion Criteria: - Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin, thienopyridines, cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequately pre-medicated - History of an allergic reaction or significant sensitivity to drugs such as zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative - History of a stroke or transient ischemic attack (TIA) within the prior 6 months - Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months - History of bleeding diathesis or coagulopathy or will refuse blood transfusions - Concurrent medical condition with a life expectancy of less than 12 months - Currently participating in an investigational drug or another device trial that has not completed the primary endpoint - Documented left ventricular ejection fraction (LVEF) < 30% at the most recent evaluation

Additional Information

Official title A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study
Principal investigator Matthew J. Price, MD, FACC, FSCAI
Trial information was received from ClinicalTrials.gov and was last updated in April 2017.
Information provided to ClinicalTrials.gov by Medtronic Vascular.